Reviewing Component Mechanisms of Peripheral CB1 Inhibitor Antibody

Date published: September 4, 2025 3:00 pm PDT

Skye’s CMO and CSO discuss key differentiating mechanistic components of our peripherally-restricted CB1-inhibiting antibody, nimacimab.